Sepsis-induced acute lung injury: AUF1 regulates pyroptosis via ETS2/ZDHHC21-mediated STING palmitoylation Authors: Mingwang Jia, Fang Peng, Peng Xu, Yuanhang Fan, Jiao Liu, Biying Luo, Wanrong Wu, Yinling Wang, Zhenhui Zhang, Yichun Wang Published: 2025 ABSTRACT BackgroundSepsis-induced acute lung injury (ALI) is characterized by excessive inflammation and pyroptosis of lung epithelial cells. AU-rich element binding factor 1 (AUF1) is a key RNA-binding protein involved in mRNA decay and regulation of inflammatory responses. Understanding AUF1’s role in ALI could reveal novel therapeutic targets.MethodsWe employed both in vivo (cecal ligation and puncture, CLP) and in vitro (lipopolysaccharide, LPS-treated cells) models of sepsis-induced ALI. Survival rates, lung histopathology, and expression levels of ZDHHC21, STING palmitoylation, and pyroptosis markers (c-Caspase-1, GSDMD-N, IL-18, IL-1β) were assessed. Knockdown and overexpression experiments for ZDHHC21, ETS2, and AUF1 were conducted. RNA immunoprecipitation (RIP) and RNA pulldown assays evaluated AUF1 binding to ETS2 mRNA, while mRNA decay was analyzed using actinomycin D.ResultsIn ALI models, ZDHHC21 expression, STING palmitoylation, and pyroptosis markers were significantly increased. Inhibition of NLRP3/AIM2 improved survival and reduced lung injury without affecting ZDHHC21 levels. Knockdown of ZDHHC21 reduced STING palmitoylation and pyroptosis. ETS2 was upregulated in ALI and directly activated ZDHHC21 transcription. AUF1 expression was downregulated in ALI, leading to decreased decay of ETS2 mRNA and elevated ETS2/ZDHHC21/STING axis activity. Overexpression of AUF1 reversed these changes, reducing STING palmitoylation and pyroptosis. AUF1 directly bound and promoted the decay of ETS2 mRNA.ConclusionAUF1 mitigates sepsis-induced ALI by promoting ETS2 mRNA decay via the ETS2/ZDHHC21 axis, thereby reducing STING palmitoylation and pyroptosis in lung epithelial cells. Targeting the AUF1/ETS2/ZDHHC21/STING pathway offers a promising therapeutic strategy for improving outcomes in sepsis-induced ALI. Future studies should validate these findings in human samples and explore upstream regulators of AUF1.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00018-025-06038-4. Introduction Sepsis is a systemic inflammatory response syndrome triggered by infection, characterized by significant organ dysfunction [1]. With a mortality rate ranging from 30% to 50%, sepsis stands as one of the leading causes of death in intensive care units [2]. A common complication of sepsis is acute lung injury (ALI), characterized by pulmonary inflammation and impaired gas exchange, which can result in severe respiratory failure [3]. Current therapeutic strategies for ALI, including supportive care, fluid management, and antibiotics, offer limited improvements due to its complex etiology [4]. Recent research has highlighted the significant role of pyroptosis, a type of programmed cell death characterized by the rupture of cell membranes and the release of inflammatory mediators, in the development of multiple organ failure associated with sepsis [5]. Pyroptosis exacerbates local inflammation and damages surrounding healthy cells, creating a vicious cycle [6]. Inhibiting pyroptosis has shown promise in alleviating sepsis-induced ALI and improving clinical outcomes [7]. For instance, a study by Zhang et al. demonstrated that ETV5 can inhibit pyroptosis to ameliorate ALI symptoms [8]. These findings highlight the potential of targeting pyroptosis as a therapeutic strategy for ALI induced by sepsis, providing new insights for improving patient prognosis. The Stimulator of Interferon Genes (STING) is a crucial intracellular signaling protein regulating immune responses and inflammation [9]. Recent studies link STING activation and pyroptosis. In lipopolysaccharide (LPS)-induced ALI, mitochondrial DNA (mtDNA) and the transcription factor c-Myc activate the STING pathway, worsening inflammation by triggering NLRP3 inflammasome [10]. Furthermore, the STING agonist diABZI induces STING activation and dimerization, enhancing apoptosis, pyroptosis, and necrosis, which increases pulmonary inflammation and acute respiratory distress syndrome [11]. Conversely, inhibiting STING activation can reduce pyroptosis and alleviate sepsis-induced ALI. For example, Peng et al. demonstrated that negative regulation of the STING signaling decreases NLRP3 activation, reduces macrophage pyroptosis, and improves ALI in mice [12]. The results indicate that modulating STING activation could present innovative treatment strategies for sepsis-associated ALI, underscoring the critical involvement of STING in the disease’s underlying mechanisms. Palmitoylation is a widely studied post-translational modification that regulates protein stability, localization, and interactions [13]. Dysregulation of palmitoylation is associated with numerous diseases, including metabolic syndrome, cancer, and infections [14]. STING activation depends on its palmitoylation, and inhibiting this modification can alleviate STING-induced inflammation, making it a potential therapeutic target for inflammatory diseases [15]. The Zinc Finger Asp-His-His-Cys (ZDHHC) family of palmitoyl S-acyltransferases (PATs) [16], especially ZDHHC21, plays a crucial role in sepsis-related tissue damage. Yang et al. demonstrated that ZDHHC21-mediated palmitoylation of the α1-adrenergic receptor (α1AR) impairs renal function during sepsis, whereas ZDHHC21 deficiency preserves renal perfusion and oxygenation, making ZDHHC21 a novel regulator of renal function during septic injury [17]. Additionally, inhibition of ZDHHC21 reduces extracellular vesicles (EVs) palmitoylation, resulting in decreased neutrophil infiltration and improved survival rates in sepsis models [18]. These studies highlight ZDHHC21’s critical role in sepsis-associated palmitoylation. However, it remains unclear whether ZDHHC21 can regulate STING palmitoylation and influence ALI progression, warranting further investigation. E26 Transformation Specific-2 (ETS2) is a transcription factor and proto-oncogene in the ETS family, but the specific function of ETS2 in inflammatory responses remains unclear [19]. Studies show contradictory findings regarding ETS2’s role, with some indicating pro-inflammatory effects [20] and others suggesting anti-inflammatory roles [21], depending on the context. In our study, we observed an increased ETS2 expression in a sepsis-induced ALI model, correlating with inflammatory responses, suggesting ETS2’s involvement in sepsis-related inflammation. Bioinformatics analysis also identified ETS2 binding sites in the promoter region of ZDHHC21, supporting a potential regulatory relationship, though no literature evidence exists. Further investigation is needed to explore whether ETS2 regulates ZDHHC21 and contributes to STING palmitoylation-mediated pyroptosis, providing insights into ETS2’s role in inflammatory mechanisms. AU-rich element (ARE)-binding factor 1 (AUF1), also known as heterogeneous nuclear ribonucleoprotein D (hnRNP D), binds to AU-rich sequences in mRNA 3’ untranslated regions (UTR) to regulate mRNA decay [22]. AUF1 has been reported to prevent ferritin deposition by modulating NRF2 and ATF3 expression, thereby alleviating sepsis-induced ALI [23]. However, its role in ALI inflammation through pyroptosis remains unexplored. Bioinformatics analysis (PRIseq) revealed a strong binding affinity between AUF1 and ETS2 mRNA, suggesting that AUF1 may mediate the decay of ETS2 mRNA, thereby influencing ETS2 expression levels. This regulation could subsequently lead to the transcriptional control of ZDHHC21, ultimately affecting STING palmitoylation and its mediated pyroptosis. Notably, no literature has reported on AUF1’s role in ETS2 mRNA decay or its impact on ZDHHC21 and STING. Investigating these relationships may provide crucial insights into the molecular mechanisms underlying ALI and pyroptosis, potentially offering new therapeutic targets. Methods Animals Male C57BL/6 mice, aged 8–10 weeks and weighing 20–25 g, were sourced from Wei Ran Biology (Guangzhou, China). The animals were maintained in a pathogen-free environment with controlled lighting (12-hour light/dark cycles) and provided unrestricted access to food and water. All protocols were reviewed and approved by the Laboratory Animal Ethics Committee of Guangzhou Medical University and adhered to the ethical standards outlined by the National Institutes of Health (NIH) for the humane treatment of research animals. The study comprised three experimental groups, each consisting of eight mice: Sham Group: Mice underwent a Sham operation without cecal ligation and puncture (CLP). CLP Group: Mice were subjected to CLP-induced sepsis to model ALI. CLP + NLRP3/AIM2-IN-3 Group: CLP-induced sepsis mice received intraperitoneal injections of the NLRP3/AIM2 inhibitor NLRP3/AIM2-IN-3 (Cat: HY-144226, MedChemExpress, NJ, USA) at a dose of 10 mg/kg immediately after surgery. Cecal Ligation and Puncture (CLP) procedure To induce sepsis, the CLP method was performed as previously described [24]. Briefly, after anesthesia with isoflurane, a midline incision was made in the lower abdomen to expose the cecum. The cecum was ligated at two-thirds of its length using a 4 − 0 silk suture and punctured once with a 21-gauge needle to allow fecal matter to extrude, inducing polymicrobial sepsis. In the Sham group, the cecum was exposed but neither ligated nor punctured. The abdomen was then closed in two layers using absorbable sutures, and mice were resuscitated with sterile saline administered subcutaneously. Kaplan-Meier survival analysis Survival rates were monitored daily for 3 days post-CLP. Survival analysis was conducted using GraphPad Prism (v10.1.2), with Kaplan-Meier curves plotted to evaluate and compare the likelihood of survival across the various experimental groups. The log-rank (Mantel-Cox) test, performed in GraphPad Prism (v10.1.2), was utilized to determine the statistical significance of differences observed in the data. Cells culture The MLE-12 murine lung epithelial cell line, sourced from Guangzhou Xinyuan Biotechnology, was cultured in DMEM/F-12 medium (Gibco, Cat: 11320033, MA, USA) enriched with 10% fetal bovine serum (Thermo Fisher, Cat: 10099141 C, MA, USA), along with 100 U/mL penicillin and 100 µg/mL streptomycin (Hyclone, Cat: SV30010, MA, USA). Human pulmonary alveolar epithelial cell (hPAEpiCs) were obtained Sunncell (Wuhan, Hubei) and cultured in the hPAEpiC human alveolar epithelial cell-specific medium (Sunncell, Wuhan). The cells were incubated at 37 °C in a 5% CO₂ atmosphere within a humidified chamber and grown in tissue culture flasks until they reached around 80% confluency. Prior to experimental procedures, the cells were plated and given time to attach overnight. Cell viability assay (CCK-8) The viability of MLE-12 cells and hPAEpiCs was evaluated using the CCK-8 assay (Dojindo Molecular Technologies), following the protocol provided by the manufacturer. Cells were plated in 96-well plates at a concentration of 5 × 10³ cells per well and allowed to attach overnight. After applying the specified treatments, 10 µL of CCK-8 reagent was introduced into each well and incubated for 1–4 h at 37 °C. The absorbance was then recorded at 450 nm using a microplate reader (BioTek Epoch 2, WA, USA). Cell treatment To induce an ALI-like state, MLE-12 cells and hPAEpiCs were treated with lipopolysaccharide (LPS, Sigma-Aldrich, Darmstadt, Germany) at a final concentration of 1 µg/mL for 24 h. For inhibitor studies, cells were pretreated with the NLRP3/AIM2-IN-3 (Cat: HY-144226, MedChemExpress, NJ, USA) at 10 µM for 1 h before LPS stimulation. Overexpression of AUF1 and ETS2 in MLE-12 cells Cells were transiently transfected with pcDNA3.0 plasmids encoding AUF1, ETS2, or both using Lipofectamine 3000 transfection reagent (Thermo Fisher, MA, USA) according to the manufacturer’s protocol. Following transfection, cells were incubated for 24 h before LPS or other treatment. Cells transfected with empty vector plasmids served as negative controls (NC). Additionally, untreated cells served as baseline controls. Knockdown of ETS2 and ZDHHC21 in MLE-12 cells For gene knockdown, cells were transfected with shRNA plasmids targeting ETS2 (sh-ETS2) or ZDHHC21 (sh-ZDHHC21) (RiboBio, Guangzhou, China), along with a non-targeting control shRNA plasmid (sh-NC), using Lipofectamine 3000 (Thermo Fisher, MA, USA) reagent according to the manufacturer’s instructions. Cells were incubated for an additional 24 h before LPS or other treatment. Quantitative real-time PCR (qRT-PCR) RNA isolation was performed with TRIzol reagent (Thermo Fisher, MA, USA) in accordance with the provided protocol. RNA was quantified using a NanoDrop ND1000 spectrophotometer (Thermo Fisher, MA, USA) and reverse transcribed into cDNA using the HiScript II Reverse Transcriptase Kit (Vazyme, Nanjing, China). Quantitative real-time PCR was conducted with SYBR Green Master Mix (Bio-Rad) using a Bio-Rad CFX96 Real-Time PCR System. The expression levels of target genes were quantified and normalized against the internal control GAPDH, employing the 2⁻ΔΔCT approach for analysis. Flow cytometry Pyroptosis levels were evaluated by measuring Caspase-1 and propidium iodide (PI) positivity using flow cytometry. After treatment, MLE-12 cells were harvested and washed with cold PBS. Cells were subsequently stained with FITC-conjugated Caspase-1 (1:100 dilution, NB100-56565 F, Novus, CO, USA) and PI (1 µg/mL, Thermo Fisher, MA, USA) according to the manufacturer’s instructions. Stained cells were incubated on ice in the dark for 30 min. Samples were analyzed using a flow cytometer (BD FACSCanto, CA, USA) and data were processed using FlowJo software (version 10). Lung tissue histology and injury scoring Mice were sacrificed 72 h after CLP, and their lung tissues were collected, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at a thickness of 5 μm. The tissue sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin following standard protocols. Stained slides were examined under a light microscope (Olympus BX53, TKY, JP). Lung injury was quantitatively assessed using a standardized histological scoring system based on parameters such as alveolar congestion, hemorrhage, inflammatory cell infiltration, and thickness of the alveolar walls. Each factor was evaluated on a scale of 0 to 4, where higher values correspond to increased injury severity. The total injury score for each sample was the sum of the individual parameter scores. Scoring was performed blinded to the experimental groups by two independent observers. Acyl-Resin-Assisted Capture (Acyl-RAC) assay for STING palmitoylation STING palmitoylation levels in lung tissues or MLE-12 cells and hPAEpiCs were measured using the Acyl-RAC assay as described by [25]. Lung tissues or MLE-12 cells were lysed in a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, protease inhibitors, and N-ethylmaleimide (NEM) to prevent palmitoylation reversibility. Free thiols were blocked by treating the lysates with methylmethanethiosulfonate (MMTS). Palmitoyl groups were removed by hydroxylamine (HAM) treatment, converting them into free thiols. The newly formed thiols were captured using thiopropyl Sepharose resin. Proteins were eluted and analyzed via Western blot with anti-STING antibodies to quantify palmitoylation levels. Immunohistochemistry (IHC) Lung tissue sections from each group were processed for IHC staining to detect the expression of ZDHHC21, cleaved Caspase-1 (c-Caspase-1), and the cleaved form of Gasdermin D (GSDMD-N). The procedure was as follows: Sections were subjected to microwave-assisted heating in citrate buffer (pH 6.0) for 15 min. To inhibit endogenous peroxidase activity, they were treated with 3% hydrogen peroxide for 10 min. Subsequently, the sections were blocked with 5% normal goat serum in PBS for one hour. Sections were incubated overnight at 4 °C with primary antibodies against ZDHHC21 (1:200, Invitrogen, PA5-25096), c-Caspase-1 (1:200, HY-P80622; MedChemExpress), and GSDMD-N (1:200, Invitrogen, PA5-116815). Sections were washed and then incubated with biotinylated secondary antibodies (Invitrogen, 31460) at room temperature for one hour. This was followed by treatment with streptavidin-HRP for 30 min. The chromogenic reaction was developed using diaminobenzidine (DAB), and the sections were subsequently counterstained with hematoxylin. Slides were dehydrated, cleared, and mounted. Positive staining was assessed using a light microscope, and images were captured with a digital imaging system. Negative controls included sections incubated without primary antibodies to assess non-specific staining. Western blotting Lung tissues or MLE-12 cells/hPAEpiCs were lysed using RIPA buffer (Sigma-Aldrich, Darmstadt, Germany) supplemented with protease and phosphatase inhibitors. Lysates were centrifuged at 12,000 × g for 15 min at 4 °C, and supernatants were collected. Protein concentrations were measured with the BCA Protein Assay Kit (Thermo Fisher, MA, USA). An equal amount of protein (30 µg per lane) was separated by 10% SDS-PAGE and subsequently transferred to PVDF membranes (Sigma-Aldrich, Darmstadt, Germany). Membranes were blocked for one hour at room temperature with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20). Afterwards, the membranes were incubated overnight at 4 °C with primary antibodies against ZDHHC21 (1:1000, Invitrogen, PA5-25096), TBK1 (1:1000, CST, 3504), p-TBK1 (1:1000, CST, 5483T), IRF3 (1:1000, CST, 4302T), p-IRF3 (1:1000, CST, 4947T), c-Caspase-1 (1:1000, MedChemExpress, HY-P80622), GSDMD-N (1:1000, Invitrogen, PA5-116815), and β-actin (1:10,000, Invitrogen, PA5-78715) as a loading control. After washing, membranes were treated with HRP-linked secondary antibodies (1:5000, Invitrogen, 31460) at room temperature for one hour. Protein bands were then detected with an enhanced chemiluminescence (ECL) detection system (ChemiDoc MP, Bio-Rad, CA, USA) and quantified with ImageJ software (version 1.54). Enzyme-linked immunosorbent assay (ELISA) After treatment, the supernatants from MLE-12 and hPAEpiCs cell cultures were harvested and stored at − 80 °C until further analysis. The concentrations of IL-18 and IL-1β in the supernatants were measured using commercially available ELISA kits (eBioscience) following the manufacturer’s protocols. Briefly, 100 µL of standards and diluted samples were added to the respective wells of a pre-coated ELISA plate and incubated for 2 h at room temperature. After washing the plates, biotinylated detection antibodies were added and incubated for 1 h. Subsequently, the streptavidin-HRP conjugate was applied and incubated for 30 min. The plates were developed using TMB substrate, after which sulfuric acid was added to terminate the reaction. Optical density was subsequently measured at 450 nm with a microplate reader (BioTek Epoch 2, WA, USA). Cytokine concentrations were determined by comparing the sample absorbance to a standard curve provided with the kits. RNA immunoprecipitation (RIP) assay To experimentally validate the interaction between AUF1 and ETS2 mRNA in MLE-12 cells, RNA Immunoprecipitation (RIP) was performed. MLE-12 cells were lysed using RIP lysis buffer (Thermo Fisher, Cat: 89900, MA, USA) supplemented with RNase inhibitors. The lysates were incubated with an antibody specific to AUF1 (CST, 12382T, MA, USA) or a non-specific IgG control (CST, 3900, MA, USA) overnight at 4 °C with gentle rotation. Protein A/G magnetic beads (Pierce, 88802, MA, USA) were then added to capture the antibody-RNA complexes and incubated for 2 h. After extensive washing to remove non-specifically bound materials, the RNA was isolated with TRIzol reagent (Thermo Fisher, MA, USA) and subjected to reverse transcription followed by quantitative real-time PCR (RT-qPCR) to quantify ETS2 mRNA levels. RNA pulldown assay To further confirm the binding between AUF1 and ETS2 mRNA, an RNA pulldown assay was conducted. Biotinylated ETS2 mRNA probes were synthesized by MegaScript™ T7 Transcription Kit Plus (Invitrogen, A57622, MA, USA) and incubated with cell lysates from MLE-12 cells overexpressing AUF1. Streptavidin-coated magnetic beads (Pierce, 88816, MA, USA) were added to capture the biotinylated mRNA-protein complexes. After incubation and washing to eliminate non-specific interactions, the bound proteins were eluted and analyzed by Western blotting using an anti-AUF1 antibody (CST, 12382T, MA, USA) to confirm the presence of AUF1. mRNA decay assay with actinomycin D To investigate the stability of ETS2 mRNA upon AUF1 overexpression, an mRNA decay assay was performed. MLE-12 cells were transfected with AUF1 overexpression plasmid or an empty vector control and allowed to incubate for 24 h. Actinomycin D (5 µg/mL, Sigma-Aldrich) was then added to halt transcription. Cells were harvested at various time points (0, 4, and 8 h), and total RNA was extracted using TRIzol reagent (Thermo Fisher, MA, USA). Reverse transcription followed by quantitative real-time PCR (RT-qPCR) was conducted to measure the remaining levels of ETS2 mRNA, normalized to GAPDH mRNA levels. Chromatin Immunoprecipitation (ChIP) assay To determine whether ETS2 binds to the promoter region of ZDHHC21, a Chromatin Immunoprecipitation (ChIP) assay was performed. MLE-12 cells and and HPAEpiCs were cross-linked with 1% formaldehyde, and chromatin was sheared into 200–500 bp fragments by sonication. The sheared chromatin was immunoprecipitated using an ETS2-specific antibody (CST, 33386T, MA, USA) or a non-specific IgG control (CST, 3900, MA, USA). Following immunoprecipitation, cross-links were reversed, and DNA was purified using a ChIP kit (Sigma-Aldrich, 17–295, Darmstadt, Germany). The presence of ZDHHC21 promoter regions in the immunoprecipitated DNA was evaluated by quantitative real-time PCR (qRT-PCR) to the ZDHHC21 promoter. Dual-luciferase reporter assay To evaluate the regulatory impact of ETS2 on the ZDHHC21 promoter, a dual-luciferase reporter assay was conducted. MLE-12 cells were transfected with either the wild-type or BS1 mutant ZDHHC21 promoter luciferase plasmid (constructed using the pGL3-basic vector from Promega, WI, USA), along with an ETS2 shRNA plasmid or control shRNA plasmid, and incubated for 48 h. Following transfection, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, E1910, WI, USA). Firefly luciferase activity was normalized to Renilla luciferase activity to assess the relative promoter activity. Human lung tissue collection Human ALI lung tissues were obtained from sepsis patients, and control tissues were collected from adjacent non-tumorous lung regions of patients undergoing resection for localized lung cancer. The diagnosis of sepsis and ALI was confirmed based on the Sepsis-3 and Berlin criteria. All samples were histologically verified, and patients with chronic pulmonary diseases were excluded. The study was approved by the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University, and written informed consent was obtained from the patients or their next of kin. Statistical analysis All data are presented as mean ± standard deviation (SD). Statistical analyses were performed using GraphPad Prism (version 10.1.2). A two-tailed Student’s t-test was used to compare the two groups. For assessing differences across multiple groups, one-way analysis of variance (ANOVA) was performed followed by Tukey’s post hoc test for multiple comparisons. Survival analyses were conducted using the log-rank (Mantel-Cox) test. A p-value of < 0.05 was considered statistically significant. Each experiment was independently repeated at least three times unless otherwise stated. Results Enhances pyroptosis and STING palmitoylation alongside elevated ZDHHC21 expression during Sepsis-Induced acute lung injury In this research, we utilized the cecal ligation and puncture (CLP) to create a mouse ALI model, a method that closely mimics the clinical manifestations of sepsis-related ALI. Mice were categorized into three groups: Sham-operated, CLP-induced sepsis, and CLP-induced sepsis treated with the NLRP3/AIM2 inhibitor NLRP3/AIM2-IN-3 (CLP + NLRP3/AIM2-IN-3). The inclusion of the NLRP3/AIM2-IN-3 group was essential to inhibit inflammasome-mediated pyroptosis, thereby demonstrating the critical role of pyroptosis in lung injury. Kaplan-Meier survival analysis (Fig. 1A) revealed a reduction in survival rates in the CLP group compared to the Sham group. Treatment with the NLRP3/AIM2 inhibitor NLRP3/AIM2-IN-3 in the CLP + NLRP3/AIM2-IN-3 group resulted in an improvement in survival rates, indicating the protective effect of inhibiting the NLRP3/AIM2 pathway. Histopathological examination using hematoxylin and eosin (HE) staining (Fig. 1B) demonstrated pronounced pathological changes in the lung tissues of CLP mice, including increased inflammatory cell infiltration and alveolar wall thickening compared to Sham-operated mice. These observations were further corroborated by a quantitative assessment of lung injury scores (Fig. 1C), which showed an elevation in the CLP group. Treatment with NLRP3/AIM2-IN-3 significantly attenuated these pathological changes and reduced lung injury scores, suggesting that inhibition of the NLRP3/AIM2 pathway ameliorates lung damage. To elucidate the molecular mechanisms underlying these effects, we assessed STING palmitoylation levels using the Acyl-resin-assisted capture (Acyl-RAC) assay (Fig. 1D). Relative to the Sham group, the CLP group exhibited an increase in STING palmitoylation, and STING palmitoylation levels remained elevated in the CLP + NLRP3/AIM2-IN-3 group. This suggests that STING acts upstream of the NLRP3/AIM2 pathway in mediating pyroptosis. Additionally, we investigated the expression of ZDHHC21, a member of the zinc finger DHHC-type family responsible for STING palmitoylation, using immunohistochemistry (IHC) and Western blot analyses (Fig. 1E and F). CLP-induced sepsis led to elevated ZDHHC21 levels compared to Sham-operated mice. However, treatment with the NLRP3/AIM2 inhibitor NLRP3/AIM2-IN-3 did not alter ZDHHC21 expression, indicating that ZDHHC21 upregulation is independent of inflammasome-mediated pyroptosis. In line with this observation, phosphorylation levels of TBK1 and IRF3 were enhanced following CLP challenge and were not influenced by NLRP3/AIM2 inhibition (Fig. 1F). Furthermore, we examined pyroptosis-related proteins and inflammatory cytokines. IHC and Western blot assays revealed increased expression of c-Caspase-1 and Gasdermin D-N-terminal fragment (GSDMD-N) in the CLP group, which were significantly reduced upon treatment with NLRP3/AIM2-IN-3 (Fig. 1E and F). Additionally, ELISA measurements confirmed elevated levels of the inflammatory cytokines IL-18 and IL-1β in the CLP group, which were attenuated by the inhibitor treatment (Fig. 1G). Consistently, analysis of human septic ALI tissues showed markedly increased expression of ZDHHC21, GSDMD-N, p-TBK1, and p-IRF3 compared with control lung tissues (Figure S1A). In addition, as shown in Figure S1B, STING palmitoylation modification is significantly upregulated in septic ALI. Fig. 1Assessment of survival, lung pathology, STING palmitoylation, and inflammatory markers in sepsis-induced acute lung injury. The cecal ligation and puncture (CLP) model was utilized to create sepsis-related acute lung injury (ALI). Samples were harvested for analysis 72 h after CLP. The NLRP3/AIM2-IN-3 group received an intravenous injection through the tail vein immediately after CLP induction at a dose of 10 mg/kg. (A) Survival rates were compared using Kaplan-Meier survival curves among Sham-operated mice, CLP-induced sepsis mice, and CLP-induced sepsis mice treated with the NLRP3/AIM2 inhibitor NLRP3/AIM2-IN-3 (CLP + NLRP3/AIM2-IN-3). (B) Lung tissues from Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups were subjected to hematoxylin and eosin (HE) staining for assessment of pathological changes (scale bar = 100 μm). (C) Lung injury was quantitatively assessed based on histological criteria, providing injury scores for Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups. (D) STING palmitoylation levels in lung tissues were measured using the Acyl-resin-assisted capture (Acyl-RAC) assay in Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups. (E) Lung tissue sections underwent immunohistochemistry (IHC) staining to assess the expression of ZDHHC21, cleaved Caspase-1 (c-Caspase-1), and the cleaved form of Gasdermin D (GSDMD-N) in Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups (scale bar = 100 μm). (F) Protein levels of ZDHHC21,TBK1, p-TBK1, IRF3, p-IRF3, c-Caspase-1, and GSDMD-N were quantified in lung tissues from Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups using Western blotting. (G) Levels of the inflammatory cytokines IL-18 and IL-1β in lung tissues were measured by enzyme-linked immunosorbent assay (ELISA) in Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups. Data are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. n = 8 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 Assessment of survival, lung pathology, STING palmitoylation, and inflammatory markers in sepsis-induced acute lung injury. The cecal ligation and puncture (CLP) model was utilized to create sepsis-related acute lung injury (ALI). Samples were harvested for analysis 72 h after CLP. The NLRP3/AIM2-IN-3 group received an intravenous injection through the tail vein immediately after CLP induction at a dose of 10 mg/kg. (A) Survival rates were compared using Kaplan-Meier survival curves among Sham-operated mice, CLP-induced sepsis mice, and CLP-induced sepsis mice treated with the NLRP3/AIM2 inhibitor NLRP3/AIM2-IN-3 (CLP + NLRP3/AIM2-IN-3). (B) Lung tissues from Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups were subjected to hematoxylin and eosin (HE) staining for assessment of pathological changes (scale bar = 100 μm). (C) Lung injury was quantitatively assessed based on histological criteria, providing injury scores for Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups. (D) STING palmitoylation levels in lung tissues were measured using the Acyl-resin-assisted capture (Acyl-RAC) assay in Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups. (E) Lung tissue sections underwent immunohistochemistry (IHC) staining to assess the expression of ZDHHC21, cleaved Caspase-1 (c-Caspase-1), and the cleaved form of Gasdermin D (GSDMD-N) in Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups (scale bar = 100 μm). (F) Protein levels of ZDHHC21,TBK1, p-TBK1, IRF3, p-IRF3, c-Caspase-1, and GSDMD-N were quantified in lung tissues from Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups using Western blotting. (G) Levels of the inflammatory cytokines IL-18 and IL-1β in lung tissues were measured by enzyme-linked immunosorbent assay (ELISA) in Sham, CLP, and CLP + NLRP3/AIM2-IN-3 groups. Data are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. n = 8 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 Collectively, these findings demonstrate that sepsis-induced ALI is associated with increased STING palmitoylation and elevated ZDHHC21 expression. Inhibition of the NLRP3/AIM2 pathway effectively reduces pyroptosis and the production of inflammatory cytokines without affecting ZDHHC21 expression or STING palmitoylation. These results highlight the pivotal role of inflammasome-mediated pyroptosis in lung injury and suggest that ZDHHC21-mediated STING palmitoylation operates upstream of the NLRP3/AIM2 inflammasome in the inflammatory cascade of ALI. ZDHHC21 enhances STING palmitoylation and promotes pyroptosis in an in vitro sepsis-induced ALI model To validate our in vivo findings and establish a cellular basis for exploring the underlying mechanisms, we employed an in vitro sepsis-related ALI model using mouse lung epithelial MLE-12 cells stimulated with lipopolysaccharide (LPS). Additionally, we treated these cells with NLRP3/AIM2-IN-3 to inhibit LPS-induced pyroptosis. Cell viability, assessed using the CCK-8 assay, was significantly reduced in the LPS-treated group compared to the control (Fig. 2A). However, co-treatment with NLRP3/AIM2-IN-3 notably enhanced cell viability relative to the LPS-only group, suggesting a protective effect against LPS-induced cytotoxicity. Flow cytometry analysis further revealed that LPS stimulation markedly increased the proportions of PI-positive and Caspase-1-positive cells compared to controls (Fig. 2B). Treatment with NLRP3/AIM2-IN-3 effectively reversed the LPS-induced elevation of pyroptosis, indicating that inhibition of the NLRP3/AIM2 pathways mitigates pyroptotic cell death. To investigate the role of STING palmitoylation in this process, we performed Acyl-RAC assays, which demonstrated a significant increase in STING palmitoylation in the LPS-treated cells compared to controls (Fig. 2C). Importantly, the addition of NLRP3/AIM2-IN-3 did not prevent this increase, suggesting that STING acts upstream of the NLRP3/AIM2 inflammasome in regulating pyroptosis. Consistent with our in vivo observations, Western blot results revealed that ZDHHC21 was significantly upregulated following LPS treatment (Fig. 2D). However, NLRP3/AIM2-IN-3 did not alter ZDHHC21 levels, indicating that ZDHHC21 expression is independent of NLRP3/AIM2 regulation. Consistent with this, levels of p-TBK1 and p-IRF3 were increased after LPS treatment and remained unchanged by NLRP3/AIM2 inhibition (Fig. 2D). Furthermore, the expression levels of pyroptosis-related proteins c-Caspase-1 and GSDMD-N were significantly elevated in the LPS group compared to controls (Fig. 2D). Treatment with NLRP3/AIM2-IN-3 significantly reduced the levels of these proteins. Additionally, we used ELISA to measure the levels of IL-1β and IL-18 in the cell culture supernatant, which showed trends consistent with the expression of c-Caspase-1 and GSDMD-N (Fig. 2E). These results collectively demonstrate that LPS stimulation decreases MLE-12 cell viability and elevates pyroptosis, which can be attenuated by inhibiting the NLRP3/AIM2 inflammasome pathways. Additionally, STING palmitoylation and ZDHHC21 expression are upregulated by LPS treatment, with STING functioning upstream of NLRP3/AIM2-mediated pyroptosis. This comprehensive in vitro analysis not only corroborates our in vivo findings but also provides a solid foundation for further mechanistic studies. Fig. 2Evaluation of cell viability, pyroptosis, STING palmitoylation, and inflammatory markers in an in vitro sepsis-induced acute lung injury model. MLE-12 cells were stimulated with LPS (1 µg/mL) to induce a sepsis-induced ALI cell model, with the control group receiving an equivalent volume of PBS. All assays were performed 24 h after LPS stimulation. The NLRP3/AIM2-IN-3 group was treated with 10 µM of NLRP3/AIM2-IN-3 1 h prior to LPS stimulation. (A) The CCK-8 assay was conducted to assess the cell viability in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (B) Proportions of PI-positive and Caspase-1-positive cells were analyzed by flow cytometry in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (C) STING palmitoylation levels were assessed using the Acyl-resin-assisted capture (Acyl-RAC) assay in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (D) ZDHHC21, TBK1, p-TBK1, IRF3, p-IRF3, cleaved Caspase-1 (c-Caspase-1), and GSDMD-N protein expression were determined by Western blot analysis in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (E) IL-1β and IL-18 concentrations in the cell culture supernatant were measured by ELISA in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. Data are presented as mean ± SD. Statistical significance was assessed using one-way ANOVA followed by Tukey’s post hoc test. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 Evaluation of cell viability, pyroptosis, STING palmitoylation, and inflammatory markers in an in vitro sepsis-induced acute lung injury model. MLE-12 cells were stimulated with LPS (1 µg/mL) to induce a sepsis-induced ALI cell model, with the control group receiving an equivalent volume of PBS. All assays were performed 24 h after LPS stimulation. The NLRP3/AIM2-IN-3 group was treated with 10 µM of NLRP3/AIM2-IN-3 1 h prior to LPS stimulation. (A) The CCK-8 assay was conducted to assess the cell viability in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (B) Proportions of PI-positive and Caspase-1-positive cells were analyzed by flow cytometry in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (C) STING palmitoylation levels were assessed using the Acyl-resin-assisted capture (Acyl-RAC) assay in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (D) ZDHHC21, TBK1, p-TBK1, IRF3, p-IRF3, cleaved Caspase-1 (c-Caspase-1), and GSDMD-N protein expression were determined by Western blot analysis in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. (E) IL-1β and IL-18 concentrations in the cell culture supernatant were measured by ELISA in control, LPS, and LPS + NLRP3/AIM2-IN-3 treated MLE-12 cells. Data are presented as mean ± SD. Statistical significance was assessed using one-way ANOVA followed by Tukey’s post hoc test. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 ZDHHC21 mediates STING palmitoylation and pyroptosis in LPS-induced MLE-12 cells and hPAEpiCs To further investigate the regulatory role of ZDHHC21 on STING palmitoylation, we constructed ZDHHC21 knockdown MLE-12 cells and hPAEpiCs using shRNA and confirmed the knockdown efficiency via Western blot analysis (Figs. 3A and S2A). Subsequently, these cells were treated with LPS to examine changes in ZDHHC21 expression. Western blot results indicated that, compared to the control group, ZDHHC21 expression was upregulated in both the LPS and LPS + shNC groups, whereas the LPS + shZDHHC21 group exhibited a significant reduction in ZDHHC21 levels relative to the LPS + shNC group, confirming effective knockdown even after LPS stimulation (Figs. 3B and S2B). Assessment of cell viability using the CCK-8 assay indicated a reduction in viability in the LPS group relative to the control, whereas ZDHHC21 knockdown in the presence of LPS led to a significant increase in viability (Figs. 3C and S2C). Furthermore, flow cytometry analysis demonstrated increased Caspase-1/PI-positive cells in the LPS-treated group, which was attenuated by ZDHHC21 knockdown (Figs. 3D and S2D). Acyl-RAC assays showed that STING palmitoylation was elevated in the LPS group compared to the control, and this increase was inhibited in the LPS + shZDHHC21 group (Figs. 3E and S2E). Additionally, the results of western blot analysis indicated that the pyroptosis-related proteins c-Caspase-1 and GSDMD-N expression levels were elevated following LPS stimulation, which were significantly reduced upon ZDHHC21 knockdown (Figs. 3F and S2F). Consistent with this, the levels of p-TBK1 and p-IRF3 were also upregulated by LPS treatment; conversely, either knocking down ZDHHC21 reversed the LPS-induced elevation of these phosphorylated proteins (Figs. 3F and S2F). ELISA measurements of cell culture supernatant demonstrated similar trends, with increased levels of IL-1β and IL-18 in the LPS group, and their reduction following ZDHHC21 knockdown (Figs. 3G and S2G). These results indicate that ZDHHC21 mediates LPS-induced STING palmitoylation, leading to decreased cell viability and increased pyroptosis, which can be reversed by ZDHHC21 knockdown. Fig. 3ZDHHC21 knockdown inhibits STING palmitoylation and pyroptosis in LPS-treated MLE-12 cells. (A) Western blot to verify successful knockdown of ZDHHC21 in control and shRNA-treated MLE-12 cells. (B) Western blot analysis of ZDHHC21 expression in control, LPS, LPS + shNC, and LPS + shZDHHC21 groups. (C) Cell viability was assessed using the CCK-8 assay across different treatment groups. (D) Flow cytometry analysis of Caspase-1/PI positive rates in each group. (E) Acyl-RAC assay to evaluate STING palmitoylation levels in control, LPS, LPS + shNC, and LPS + shZDHHC21 treated cells. (F) Western blot detection of cleaved Caspase-1 (c-Caspase-1), TBK1, p-TBK1, IRF3, p-IRF3, and GSDMD-N expression levels. (G) ELISA measurements of IL-18 and IL-1β levels in cell culture supernatant. Data are presented as mean ± SD. One-way ANOVA was employed to determine statistical significance, with Tukey’s post hoc test applied afterward. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 ZDHHC21 knockdown inhibits STING palmitoylation and pyroptosis in LPS-treated MLE-12 cells. (A) Western blot to verify successful knockdown of ZDHHC21 in control and shRNA-treated MLE-12 cells. (B) Western blot analysis of ZDHHC21 expression in control, LPS, LPS + shNC, and LPS + shZDHHC21 groups. (C) Cell viability was assessed using the CCK-8 assay across different treatment groups. (D) Flow cytometry analysis of Caspase-1/PI positive rates in each group. (E) Acyl-RAC assay to evaluate STING palmitoylation levels in control, LPS, LPS + shNC, and LPS + shZDHHC21 treated cells. (F) Western blot detection of cleaved Caspase-1 (c-Caspase-1), TBK1, p-TBK1, IRF3, p-IRF3, and GSDMD-N expression levels. (G) ELISA measurements of IL-18 and IL-1β levels in cell culture supernatant. Data are presented as mean ± SD. One-way ANOVA was employed to determine statistical significance, with Tukey’s post hoc test applied afterward. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 ETS2 directly regulates ZDHHC21 transcription, modulating STING palmitoylation in LPS-induced MLE-12 cells and hPAEpiCs Building on our previous findings, we explored the significance of targeting ZDHHC21 expression in regulating STING palmitoylation and ameliorating ALI. ETS2, a crucial transcriptional regulator involved in mRNA transcription and expression, was observed to be significantly elevated in lung tissues of the CLP animal model (Fig. 4A) and in MLE-12 cells and hPAEpiCs stimulated with LPS (Figs. 4B and S3A), which showed a similar upregulation pattern in human septic ALI tissues (Figure S1A). To determine whether ETS2 governs ZDHHC21 expression, we performed ETS2 knockdown in MLE-12 cells and hPAEpiCs using shRNA. Western blot analysis confirmed a substantial reduction in ETS2 protein levels in the shETS2 group compared to the shNC control, accompanied by a corresponding decrease in ZDHHC21 expression (Figs. 4C and S3B), indicating that ETS2 regulates ZDHHC21 expression. Fig. 4ETS2 directly binds to and regulates ZDHHC21 promoter activity in CLP-induced ALI and LPS-stimulated MLE-12 Cells. (A) Western blot analysis of ETS2 expression in lung tissues from Sham and CLP-treated mice. (B) Analysis of ETS2 protein levels in control and LPS-treated MLE-12 cells was carried out using Western blot. (C) Western blot analysis showing the expression levels of ETS2 and ZDHHC21 in MLE-12 cells following ETS2 knockdown. shNC: shRNA negative control; shETS2: shRNA targeting ETS2. (D) JASPAR prediction of ETS2 binding sites on the ZDHHC21 promoter region identified three potential binding sites (BS): BS1 (-1689/-1680), BS2 (-949/-940), and BS3 (-188/-179). (E) ChIP assays were used to verify ETS2 binds to which of the three binding sites within the ZDHHC21 promoter. (F) ChIP assays showing the enrichment of the ZDHHC21 promoter at the BS1 site following ETS2 knockdown in MLE-12 cells. (G) Dual-luciferase reporter assays demonstrating the effect of ETS2 knockdown on luciferase activity in MLE-12 cells transfected with the wild-type ZDHHC21 promoter and the BS1 mutant promoter. (H) Dual-luciferase reporter assays evaluating the effect of LPS treatment on luciferase activity in cells transfected with the wild-type and BS1 mutant ZDHHC21 promoters, along with ETS2 knockdown achieved through transfection with shETS2. Data are presented as mean ± SD. To establish statistical significance, one-way ANOVA followed by Tukey’s post hoc test, as well as two-tailed Student’s t-test for comparisons between two groups was conducted. n = 8 for A, n = 3 for B-C, and E-H. *p < 0.05, **p < 0.01, ***p < 0.001 ETS2 directly binds to and regulates ZDHHC21 promoter activity in CLP-induced ALI and LPS-stimulated MLE-12 Cells. (A) Western blot analysis of ETS2 expression in lung tissues from Sham and CLP-treated mice. (B) Analysis of ETS2 protein levels in control and LPS-treated MLE-12 cells was carried out using Western blot. (C) Western blot analysis showing the expression levels of ETS2 and ZDHHC21 in MLE-12 cells following ETS2 knockdown. shNC: shRNA negative control; shETS2: shRNA targeting ETS2. (D) JASPAR prediction of ETS2 binding sites on the ZDHHC21 promoter region identified three potential binding sites (BS): BS1 (-1689/-1680), BS2 (-949/-940), and BS3 (-188/-179). (E) ChIP assays were used to verify ETS2 binds to which of the three binding sites within the ZDHHC21 promoter. (F) ChIP assays showing the enrichment of the ZDHHC21 promoter at the BS1 site following ETS2 knockdown in MLE-12 cells. (G) Dual-luciferase reporter assays demonstrating the effect of ETS2 knockdown on luciferase activity in MLE-12 cells transfected with the wild-type ZDHHC21 promoter and the BS1 mutant promoter. (H) Dual-luciferase reporter assays evaluating the effect of LPS treatment on luciferase activity in cells transfected with the wild-type and BS1 mutant ZDHHC21 promoters, along with ETS2 knockdown achieved through transfection with shETS2. Data are presented as mean ± SD. To establish statistical significance, one-way ANOVA followed by Tukey’s post hoc test, as well as two-tailed Student’s t-test for comparisons between two groups was conducted. n = 8 for A, n = 3 for B-C, and E-H. *p < 0.05, **p < 0.01, ***p < 0.001 Further investigation into the regulatory mechanism involved using the JASPAR database to predict ETS2 binding sites within the ZDHHC21 promoter region (from the transcription start site to -2000 bp), identifying three potential sites labeled BS1, BS2, and BS3 (Fig. 4D). Chromatin immunoprecipitation (ChIP) assays revealed significant enrichment of the BS1 DNA sequence (-1689/-1680) of the ZDHHC21 promoter in the ETS2 immunoprecipitated samples compared to the IgG control, while BS2 and BS3 showed no significant enrichment (Figs. 4E and S3C). Additionally, ETS2 knockdown resulted in a marked reduction in ZDHHC21 promoter enrichment at the BS1 site in ChIP assays (Figs. 4F and S3D), confirming the physical interaction between ETS2 and the ZDHHC21 promoter. To assess the functional impact of this binding, we constructed dual-luciferase reporter systems containing either the wild-type ZDHHC21 promoter or a mutant promoter with alterations at the BS1 site. In MLE-12 cells transfected with the wild-type ZDHHC21 luciferase plasmid, ETS2 knockdown significantly decreased relative luciferase activity as compared with the shNC group, whereas no significant changes were detected in cells transfected with the BS1 mutant promoter upon ETS2 knockdown (Fig. 4G). Furthermore, LPS stimulation increased luciferase activity in cells with the wild-type promoter, an effect that was attenuated by ETS2 knockdown. In contrast, LPS treatment did not affect luciferase activity in cells with the BS1 mutant promoter (Fig. 4H). These results collectively demonstrate that ETS2 directly binds to the BS1 site on the ZDHHC21 promoter to regulate its transcription, thereby modulating STING palmitoylation in the context of sepsis-induced ALI in vitro model. AUF1 overexpression inhibits ETS2/ZDHHC21-mediated STING palmitoylation and pyroptosis in sepsis-induced ALI In the CLP-induced sepsis model, we observed a significant downregulation of AUF1 protein expression in lung tissues (Fig. 5A), which was consistent with the decreased AUF1 levels observed in human septic ALI tissues (Figure S1A). A similar trend was noted in LPS-stimulated MLE-12 cells and hPAEpiCs, where AUF1 protein levels were significantly lower than those in the control group (Figs. 5B and S4A). As a prototypical AU-rich binding protein, AUF1 is vital for regulating post-transcriptional processes. To elucidate its specific function in the ALI model, we overexpressed AUF1 in MLE-12 cells and hPAEpiCs, and verified the overexpression via Western blot analysis (Figs. 5C and S4B). Interestingly, upon AUF1 overexpression, both ETS2 and ZDHHC21 protein levels were significantly decreased compared to the NC group (Figs. 5C and S4B). In non-AUF1-overexpressing MLE-12 cells treated with LPS, AUF1 levels were downregulated (Fig. 5D). Western blot results confirmed that AUF1 overexpression led to increased AUF1 levels even under LPS stimulation (Fig. 5D). Subsequent Western blot analysis of ETS2 and ZDHHC21 indicated that, in comparison to the AUF1 overexpression negative control (NC) group, the AUF1-overexpressing group exhibited significant downregulation of these proteins, effectively reversing the LPS-induced upregulation of ETS2 and ZDHHC21 (Fig. 5D). To assess whether AUF1 overexpression affects cell viability and pyroptosis, we performed CCK-8 assays and flow cytometry analyses for Caspase-1/PI positivity (Fig. 5E, and 5F). The results demonstrated that, compared to the NC group, AUF1 overexpression markedly increased cell viability and decreased the percentage of Caspase-1/PI-positive cells following LPS treatment. Additionally, Acyl-RAC assays revealed that STING palmitoylation was increased in the LPS group compared to the control, and AUF1 overexpression effectively reversed the LPS-induced increase in STING palmitoylation (Figs. 5G). Consistent with these observations, the levels of p-TBK1 and p-IRF3 were also upregulated by LPS treatment; conversely, overexpressing AUF1 reversed the LPS-induced elevation of these phosphorylated proteins (Fig. 5H). Furthermore, the expression levels of pyroptosis-related proteins c-Caspase-1 and GSDMD-N, as well as the levels of pro-inflammatory cytokines IL-1β and IL-18 in the supernatant of the cell culture, were elevated in the LPS group (Fig. 5H and I). However, AUF1 overexpression significantly decreased the levels of these proteins and cytokines, counteracting the LPS-induced upregulation. These results collectively suggest that AUF1 overexpression inhibits the ETS2/ZDHHC21-mediated STING palmitoylation and pyroptosis, thereby ameliorating the pathological state of ALI induced by sepsis. Fig. 5AUF1 overexpression inhibits ETS2/ZDHHC21-mediated STING palmitoylation and pyroptosis in sepsis-induced ALI models. (A) Western blotting was utilized to measure AUF1 levels in lung tissues from Sham and CLP-induced sepsis mice. (B) Analysis of AUF1 protein levels in control and LPS-treated MLE-12 cells was carried out using Western blot. (C) Western blot analysis showing the expression levels of AUF1, ETS2, and ZDHHC21 in MLE-12 cells following AUF1 overexpression. NC: negative control; AUF1: AUF1 overexpression group. (D) Western blot analysis of AUF1, ETS2, and ZDHHC21 expression in MLE-12 cells under different conditions, including control, LPS, LPS + NC, and LPS + AUF1 overexpression. (E) Cell viability was assessed using the CCK-8 assay across different treatment groups. (F) Flow cytometry analysis of Caspase-1/PI-positive rates to evaluate pyroptosis levels. (G) Acyl-RAC assay to evaluate STING palmitoylation levels in different groups. (H) Western blot analysis of TBK1, p-TBK1, IRF3, p-IRF3, cleaved Caspase-1 (c-Caspase-1), and GSDMD-N expression levels. (I) ELISA measurements of IL-1β and IL-18 concentrations in cell culture supernatant. Data are presented as mean ± SD. Statistical significance was evaluated through one-way ANOVA with subsequent analysis using Tukey’s post hoc test, as well as two-tailed Student’s t-test for comparisons between two groups. n = 8 for A, n = 3 for B-I. *p < 0.05, **p < 0.01, ***p < 0.001 AUF1 overexpression inhibits ETS2/ZDHHC21-mediated STING palmitoylation and pyroptosis in sepsis-induced ALI models. (A) Western blotting was utilized to measure AUF1 levels in lung tissues from Sham and CLP-induced sepsis mice. (B) Analysis of AUF1 protein levels in control and LPS-treated MLE-12 cells was carried out using Western blot. (C) Western blot analysis showing the expression levels of AUF1, ETS2, and ZDHHC21 in MLE-12 cells following AUF1 overexpression. NC: negative control; AUF1: AUF1 overexpression group. (D) Western blot analysis of AUF1, ETS2, and ZDHHC21 expression in MLE-12 cells under different conditions, including control, LPS, LPS + NC, and LPS + AUF1 overexpression. (E) Cell viability was assessed using the CCK-8 assay across different treatment groups. (F) Flow cytometry analysis of Caspase-1/PI-positive rates to evaluate pyroptosis levels. (G) Acyl-RAC assay to evaluate STING palmitoylation levels in different groups. (H) Western blot analysis of TBK1, p-TBK1, IRF3, p-IRF3, cleaved Caspase-1 (c-Caspase-1), and GSDMD-N expression levels. (I) ELISA measurements of IL-1β and IL-18 concentrations in cell culture supernatant. Data are presented as mean ± SD. Statistical significance was evaluated through one-way ANOVA with subsequent analysis using Tukey’s post hoc test, as well as two-tailed Student’s t-test for comparisons between two groups. n = 8 for A, n = 3 for B-I. *p < 0.05, **p < 0.01, ***p < 0.001 AUF1 directly binds to ETS2 mRNA and promotes its degradation Building on our previous findings that AUF1 downregulates ETS2 expression, we sought to elucidate the underlying regulatory mechanism. Using RPISeq, we predicted the interaction between AUF1 protein and ETS2 mRNA, which yielded high interaction probabilities with Random Forest (RF) and Support Vector Machine (SVM) models scoring 0.9 and 0.89, respectively (Fig. 6A). To experimentally validate this interaction, we performed RNA immunoprecipitation (RIP) assays in MLE-12 cells. Immunoprecipitation with an AUF1 antibody followed by qPCR revealed a significant enrichment of ETS2 mRNA in the AUF1 IP samples compared to the IgG control, confirming the binding between AUF1 and ETS2 mRNA (Fig. 6B). Furthermore, we conducted RNA pull-down assays using biotinylated full-length ETS2 mRNA (FL) and a negative control (NC) mRNA. Western blot analysis demonstrated the presence of AUF1 protein in the pull-down complexes with full-length ETS2 mRNA but not with the negative control mRNA, providing additional evidence of their direct interaction (Fig. 6C). To assess the impact of AUF1 overexpression on the AUF1-ETS2 mRNA interaction, we overexpressed AUF1 in MLE-12 cells and performed RIP assays. The results showed a significant increase in ETS2 mRNA enrichment in the AUF1 immunoprecipitated samples from AUF1-overexpressing cells compared to the negative control (Fig. 6D), further substantiating the specific binding between AUF1 and ETS2 mRNA. To investigate the functional consequences of this interaction, we performed RNA decay assays. MLE-12 cells overexpressing AUF1 were treated with actinomycin D to inhibit new mRNA synthesis, and the levels of ETS2 mRNA were measured post-treatment at 0, 4, and 8 h using qRT-PCR. The results revealed that AUF1 overexpression significantly accelerated the decay of ETS2 mRNA compared to the negative control, indicating that AUF1 promotes the destabilization and degradation of ETS2 mRNA (Fig. 6E). These findings collectively demonstrate that AUF1 directly binds to ETS2 mRNA and facilitates its degradation, thereby downregulating ETS2 expression. Fig. 6AUF1 directly interacts with ETS2 mRNA and promotes its degradation. (A) RPISeq prediction of the binding interaction between AUF1 protein and ETS2 mRNA, showing high interaction probabilities with Random Forest (RF) (0.9) and Support Vector Machine (SVM) (0.89) models. (B) RIP assay validating the binding between AUF1 and ETS2 mRNA in MLE-12 cells. AUF1 antibody was used to immunoprecipitate AUF1 protein from cell lysates, followed by qPCR analysis of ETS2 mRNA levels in the precipitated products. (C) Western blot analysis detecting AUF1 protein content in RNA pull-down products. Biotinylated full-length ETS2 mRNA (FL) and negative control mRNA (NC) were synthesized in vitro and used to perform pull-down with MLE-12 cell lysates (Ly.), followed by Western blot to detect AUF1 in the pull-down complexes. (D) RIP assay validating the binding between AUF1 and ETS2 mRNA in AUF1-overexpressing MLE-12 cells. NC: overexpression negative control; AUF1: AUF1 overexpression group. (E) RNA decay assay demonstrating the regulatory effect of AUF1 on ETS2 mRNA stability. AUF1-overexpressing MLE-12 cells were treated with actinomycin D, and the levels of ETS2 mRNA were measured at 0, 4, and 8 h using RT-qPCR to assess mRNA decay rates. Data are presented as mean ± SD. Statistical significance was determined using two-tailed Student’s t-test for comparisons between two groups. n = 3. **p < 0.01, ***p < 0.001 AUF1 directly interacts with ETS2 mRNA and promotes its degradation. (A) RPISeq prediction of the binding interaction between AUF1 protein and ETS2 mRNA, showing high interaction probabilities with Random Forest (RF) (0.9) and Support Vector Machine (SVM) (0.89) models. (B) RIP assay validating the binding between AUF1 and ETS2 mRNA in MLE-12 cells. AUF1 antibody was used to immunoprecipitate AUF1 protein from cell lysates, followed by qPCR analysis of ETS2 mRNA levels in the precipitated products. (C) Western blot analysis detecting AUF1 protein content in RNA pull-down products. Biotinylated full-length ETS2 mRNA (FL) and negative control mRNA (NC) were synthesized in vitro and used to perform pull-down with MLE-12 cell lysates (Ly.), followed by Western blot to detect AUF1 in the pull-down complexes. (D) RIP assay validating the binding between AUF1 and ETS2 mRNA in AUF1-overexpressing MLE-12 cells. NC: overexpression negative control; AUF1: AUF1 overexpression group. (E) RNA decay assay demonstrating the regulatory effect of AUF1 on ETS2 mRNA stability. AUF1-overexpressing MLE-12 cells were treated with actinomycin D, and the levels of ETS2 mRNA were measured at 0, 4, and 8 h using RT-qPCR to assess mRNA decay rates. Data are presented as mean ± SD. Statistical significance was determined using two-tailed Student’s t-test for comparisons between two groups. n = 3. **p < 0.01, ***p < 0.001 AUF1 mitigates STING palmitoylation-mediated pyroptosis through the ETS2/ZDHHC21 axis in sepsis-induced ALI To explore the interaction between AUF1 and the ETS2/ZDHHC21 axis in acute lung injury (ALI), MLE-12 cells and hPAEpiCs were engineered to overexpress AUF1, ETS2, or both. Western blot analysis revealed that AUF1 or ETS2 overexpression significantly increased their protein expression in contrast to the negative control (NC) (Figs. 7A and S5A). AUF1 overexpression reduced ETS2 and ZDHHC21 levels, while ETS2 overexpression elevated both proteins. Co-overexpression of AUF1 and ETS2 decreased their levels compared to ETS2 alone, suggesting partial counteraction of AUF1 on ETS2 and ZDHHC21. In LPS-treated cells to simulate sepsis-induced ALI, AUF1 levels decreased while ETS2 and ZDHHC21 levels increased (Figs. 7B and S5B). AUF1 overexpression reversed the LPS-induced changes, while ETS2 overexpression further amplified the increases in ETS2 and ZDHHC21. Notably, AUF1 inhibited the ETS2-driven upregulation of these proteins. Fig. 7AUF1 inhibits STING palmitoylation-mediated pyroptosis through the ETS2/ZDHHC21 axis in sepsis-induced ALI. (A) Western blot analysis of AUF1, ETS2, and ZDHHC21 protein expression in MLE-12 cells overexpressing AUF1, ETS2, or both. NC: negative control; AUF1: AUF1 overexpression group; ETS2: ETS2 overexpression group; AUF1 + ETS2: AUF1 and ETS2 both overexpression group. (B) Western blot analysis of AUF1, ETS2, and ZDHHC21 protein levels in MLE-12 cells treated with LPS following overexpression of AUF1, ETS2, or both. (C) CCK-8 assay measuring cell viability across different treatment groups following LPS stimulation. (D) Flow cytometry analysis of Caspase-1 and PI-positive rates to evaluate pyroptosis levels in each treatment group following LPS stimulation. (E) Acyl-RAC assay assessing STING palmitoylation levels in various treatment groups following LPS stimulation. (F) Western blot analysis of TBK1, p-TBK1, IRF3, p-IRF3, cleaved Caspase-1 (c-Caspase-1), and GSDMD-N in each treatment group following LPS stimulation. (G) ELISA measurements of pro-inflammatory cytokines IL-1β and IL-18 in cell culture supernatants across different treatment groups following LPS stimulation. Data are presented as mean ± SD. One-way ANOVA was performed to establish statistical significance, followed by Tukey’s post hoc test for detailed comparison. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 AUF1 inhibits STING palmitoylation-mediated pyroptosis through the ETS2/ZDHHC21 axis in sepsis-induced ALI. (A) Western blot analysis of AUF1, ETS2, and ZDHHC21 protein expression in MLE-12 cells overexpressing AUF1, ETS2, or both. NC: negative control; AUF1: AUF1 overexpression group; ETS2: ETS2 overexpression group; AUF1 + ETS2: AUF1 and ETS2 both overexpression group. (B) Western blot analysis of AUF1, ETS2, and ZDHHC21 protein levels in MLE-12 cells treated with LPS following overexpression of AUF1, ETS2, or both. (C) CCK-8 assay measuring cell viability across different treatment groups following LPS stimulation. (D) Flow cytometry analysis of Caspase-1 and PI-positive rates to evaluate pyroptosis levels in each treatment group following LPS stimulation. (E) Acyl-RAC assay assessing STING palmitoylation levels in various treatment groups following LPS stimulation. (F) Western blot analysis of TBK1, p-TBK1, IRF3, p-IRF3, cleaved Caspase-1 (c-Caspase-1), and GSDMD-N in each treatment group following LPS stimulation. (G) ELISA measurements of pro-inflammatory cytokines IL-1β and IL-18 in cell culture supernatants across different treatment groups following LPS stimulation. Data are presented as mean ± SD. One-way ANOVA was performed to establish statistical significance, followed by Tukey’s post hoc test for detailed comparison. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 Functional assays using the CCK-8 assay revealed that LPS treatment markedly decreased cell viability. Overexpression of AUF1 enhanced cell viability in the presence of LPS, whereas ETS2 overexpression further decreased cell viability. Importantly, overexpression of AUF1 mitigated the reduction in cell viability caused by ETS2 overexpression alone, suggesting a protective role of AUF1 against ETS2-mediated cytotoxicity (Figs. 7C and S5C). Flow cytometry analysis for Caspase-1 and PI positivity indicated that LPS treatment upregulated the ratio of pyroptotic cells. AUF1 overexpression decreased the LPS-induced increase in Caspase-1/PI-positive cells, while ETS2 overexpression exacerbated pyroptosis. Overexpression of AUF1 effectively reversed the pro-pyroptotic effects of ETS2 overexpression (Figs. 7D and S5D). Acyl-resin-assisted capture (Acyl-RAC) assays showed that STING palmitoylation was markedly increased in the LPS-treated group relative to the control. Overexpression of AUF1 reversed the LPS-induced increase in STING palmitoylation. ETS2 overexpression further enhanced STING palmitoylation levels, whereas overexpression of AUF1 attenuated this effect (Figs. 7E and S5E). Additionally, Western blot analysis of p-TBK1, p-IRF3, and pyroptosis-related proteins c-Caspase-1 and GSDMD-N, as well as ELISA measurements of pro-inflammatory cytokines IL-1β and IL-18 in the cell culture supernatant, mirrored the trends observed in STING palmitoylation. Specifically, LPS treatment upregulated p-TBK1, p-IRF3, c-Caspase-1, GSDMD-N, IL-1β, and IL-18 levels, which were significantly reduced by AUF1 overexpression. Conversely, ETS2 overexpression further elevated these markers, and AUF1 co-overexpression effectively mitigated the ETS2-induced upregulation (Fig. 7F and G, S5F, and S5G). These results collectively indicate that AUF1 exerts a protective effect in LPS-induced ALI by targeting and downregulating the ETS2/ZDHHC21 axis, thereby inhibiting STING palmitoylation and subsequent pyroptosis. Discussion ALI, a critical inflammatory condition characterized by widespread alveolar damage and impaired gas exchange, is a major complication of sepsis and significantly contributes to its high rates of morbidity and mortality worldwide [26]. The pathophysiology of sepsis-induced ALI involves a complex interplay of inflammatory mediators, immune cell dysfunction, and cellular death pathways. Among these, pyroptosis—a type of regulated cell death marked by the activation of inflammatory caspases and the formation of gasdermin pores—has emerged as a critical mechanism contributing to the inflammatory milieu and tissue damage observed in ALI [27, 28]. Despite growing recognition of pyroptosis in ALI, the precise molecular mechanisms governing this process remain inadequately understood, necessitating further investigation to identify potential therapeutic targets. Recent studies have elucidated the significance of ZDHHC21 in modulating inflammatory responses and cellular dysfunctions. For instance, ZDHHC21 deficiency has been shown to attenuate renal dysfunction during septic injury by regulating vascular function and reducing inflammatory markers, highlighting its crucial role in systemic inflammatory responses [17]. Additionally, ZDHHC21 mediates endothelial dysfunction in systemic inflammatory response syndrome by promoting the palmitoylation of key signaling proteins such as PLCβ1, which exacerbates vascular barrier leakage and leukocyte adhesion [29]. These findings collectively underscore the importance of ZDHHC21 in orchestrating inflammatory pathways and cellular responses to injury. In our current study, we observed that in both in vivo and in vitro models of sepsis-induced ALI, the expression of ZDHHC21 and the palmitoylation of STING were significantly upregulated, correlating with increased levels of pyroptosis. Importantly, the knockdown of ZDHHC21 resulted in a significant decrease in STING palmitoylation and a corresponding reduction in pyroptosis, highlighting ZDHHC21 as a critical mediator of STING-dependent inflammatory cell death in ALI. These findings are in line with previous research demonstrating that ZDHHC21-mediated palmitoylation plays a vital role in modulating inflammatory responses and cellular dysfunctions [17, 29]. However, our study extends these observations by specifically linking ZDHHC21 to the regulation of STING palmitoylation and pyroptosis in the context of ALI. This novel regulatory mechanism not only enhances our understanding of the molecular pathways involved in sepsis-induced lung injury but also identifies ZDHHC21 as a potential therapeutic target for mitigating excessive inflammation and tissue damage in ALI patients. The transcription factor ETS2 has been implicated in the regulation of inflammatory responses, with studies presenting conflicting roles in different biological contexts. On one hand, ETS2 has been shown to suppress inflammation; for example, Ma et al. demonstrated that ETS2 negatively regulates the production of pro-inflammatory cytokines such as IL-6 by inhibiting the MAPK/NF-κB signaling pathways in macrophages [21]. Similarly, He et al. reported that ETS2 reduces acute-on-chronic liver failure through the suppression of excessive inflammatory responses, highlighting its anti-inflammatory properties [30]. On the other hand, evidence also suggests that ETS2 can promote inflammation. Cheng et al. found that ETS2 determines the inflammatory state of endothelial cells in advanced atherosclerotic lesions by inducing a pro-inflammatory phenotype, thereby contributing to endothelial dysfunction [31]. These contradictory findings indicate that the role of ETS2 in inflammation may be context-dependent, varying with the type of cells involved and the specific pathological conditions. In our study, we investigated the role of ETS2 in sepsis-induced ALI and uncovered a novel pro-inflammatory function of ETS2 in this context. We observed that ETS2 expression was significantly upregulated in both in vivo and in vitro ALI models. Functional experiments revealed that the knockdown of ETS2 in MLE-12 cells led to a decrease in both ETS2 and ZDHHC21 expression. Using bioinformatics tools (JASPAR), we predicted and subsequently confirmed that ETS2 directly binds to specific sites on the ZDHHC21 promoter. Chromatin Immunoprecipitation (ChIP) assays demonstrated that ETS2 specifically binds to the BS1 site (-1689/-1680) on the ZDHHC21 promoter, and this binding was enhanced upon LPS stimulation but reduced upon ETS2 knockdown. These results indicate that ETS2 transcriptionally activates ZDHHC21, thereby modulating STING palmitoylation and promoting pyroptosis in ALI. This finding provides a mechanistic explanation for the pro-inflammatory role of ETS2 observed in our ALI models, aligning with the studies by Cheng et al. that highlight ETS2’s capacity to induce inflammatory phenotypes under certain conditions [31]. Conversely, the anti-inflammatory roles reported by Ma et al. and He et al. suggest that ETS2’s function may vary depending on the cellular environment and specific signaling pathways involved [21, 30]. Our study contributes to this nuanced understanding by demonstrating that in the context of ALI, ETS2 acts as a transcriptional activator of ZDHHC21, facilitating STING palmitoylation and enhancing inflammatory pyroptosis. This dual role of ETS2 underscores the complexity of its regulatory functions in inflammation and highlights the importance of context-specific studies to unravel its precise mechanisms of action. AU-rich element binding factor 1 (AUF1), also known as hnRNP D, is a critical RNA-binding protein (RBP) involved in the post-transcriptional regulation of mRNA stability and decay, thereby influencing the expression of various genes implicated in inflammation and immune responses [32]. AUF1 has been extensively studied in diverse biological contexts, including inflammation, cancer progression, and cellular senescence. However, existing literature presents conflicting roles of AUF1 in regulating inflammation, just like ETS2. For instance, Wang et al. demonstrated that AUF1 protects against ferroptosis and alleviates sepsis-induced ALI by regulating NRF2 and ATF3, highlighting an anti-inflammatory role [23]. In contrast, Zheng et al. reported that AUF1-mediated inhibition of autophagic lysosomal degradation contributes to Helicobacter pylori-induced inflammation, indicating a pro-inflammatory function [33]. These studies collectively underscore the context-dependent dual nature of AUF1 in modulating inflammation, varying between different cell types and pathological settings. In our current study, we elucidate a novel anti-inflammatory role of AUF1 in sepsis-induced ALI by demonstrating that AUF1 mediates the decay of ETS2 mRNA, thereby regulating the ETS2/ZDHHC21/STING axis. Specifically, we observed that AUF1 expression is downregulated in both in vivo and in vitro models of sepsis-induced ALI. This downregulation of AUF1 leads to reduced decay of ETS2 mRNA, resulting in increased ETS2 expression. Enhanced ETS2 levels subsequently upregulate ZDHHC21 expression by directly binding to its promoter region, as confirmed by ChIP assays. The upregulation of ZDHHC21 promotes the palmitoylation of STING, thereby facilitating its activation and subsequent pyroptosis of lung epithelial cells. Notably, our findings reveal that AUF1 directly targets ETS2 mRNA for decay, establishing a novel regulatory mechanism that links AUF1 to the modulation of STING-mediated inflammatory cell death in ALI. These results are consistent with the anti-inflammatory roles of AUF1 observed in previous studies [23], while also providing a mechanistic explanation for the context-dependent functions of AUF1 in inflammation. By identifying the AUF1/ETS2/ZDHHC21/STING axis as a critical pathway in ALI, our study advances the understanding of AUF1’s role in inflammatory diseases and highlights its potential as a therapeutic target. However, the mechanisms underlying AUF1 downregulation in ALI remain unclear. Previous studies have implicated oxidative stress, inflammatory cytokines, and post-translational modifications in modulating AUF1 expression and activity. In the context of ALI, the specific upstream signals—such as TLR4-mediated signaling, NF-κB activation, or epigenetic regulation—that lead to AUF1 downregulation were not addressed in this work. Future studies are warranted to elucidate these upstream regulatory mechanisms, which may provide additional therapeutic targets for ALI. In summary, our study elucidates a novel regulatory axis involving AUF1, ETS2, ZDHHC21, and STING that plays a critical role in the pathogenesis of sepsis-induced ALI (Fig. 8). The clinical implications of our research are profound. By targeting components of this newly identified regulatory pathway, it may be possible to develop novel interventions aimed at reducing pyroptosis and attenuating lung tissue damage in patients with sepsis-induced ALI. Such therapeutic strategies could significantly improve clinical outcomes and reduce the high mortality associated with this condition. However, our study has certain limitations that warrant further investigation. Firstly, while our findings are robust in animal and cell models, validation in human clinical samples is essential to confirm the translational potential of the AUF1/ETS2/ZDHHC21/STING axis in ALI. Additionally, the precise upstream signals leading to AUF1 downregulation in ALI remain unclear and require elucidation. Future studies should also explore the broader impact of this regulatory axis on other inflammatory pathways and cell types involved in ALI to fully understand its role in the disease spectrum. Moving forward, it is imperative to investigate the therapeutic feasibility of modulating AUF1 levels or disrupting its interaction with ETS2 mRNA to mitigate ALI. Moreover, exploring small molecules or genetic approaches that can specifically target components of the ZDHHC21/STING pathway may offer promising avenues for intervention. By addressing these gaps, future research can build on our findings to develop effective treatments for sepsis-induced ALI, ultimately enhancing patient survival and quality of life. Fig. 8Molecular mechanism of AUF1-regulated pyroptosis via ETS2/ZDHHC21/STING pathway in ALI. In sepsis-induced ALI, AUF1 expression is downregulated in lung epithelial cells, resulting in reduced decay of ETS2 mRNA and subsequent upregulation of ETS2. Elevated ETS2 directly activates the transcription of ZDHHC21, a palmitoyltransferase, leading to increased STING palmitoylation. Activated STING signaling promotes the phosphorylation of TBK1 and IRF3, ultimately enhancing pyroptosis via upregulation of c-Caspase-1, GSDMD-N, IL-18, and IL-1β. Overexpression of AUF1 promotes the decay of ETS2 mRNA, thereby suppressing the ETS2/ZDHHC21/STING axis, reducing STING palmitoylation and downstream pyroptosis, and alleviating lung injury. This pathway highlights AUF1 as a potential therapeutic target for sepsis-induced ALI Molecular mechanism of AUF1-regulated pyroptosis via ETS2/ZDHHC21/STING pathway in ALI. In sepsis-induced ALI, AUF1 expression is downregulated in lung epithelial cells, resulting in reduced decay of ETS2 mRNA and subsequent upregulation of ETS2. Elevated ETS2 directly activates the transcription of ZDHHC21, a palmitoyltransferase, leading to increased STING palmitoylation. Activated STING signaling promotes the phosphorylation of TBK1 and IRF3, ultimately enhancing pyroptosis via upregulation of c-Caspase-1, GSDMD-N, IL-18, and IL-1β. Overexpression of AUF1 promotes the decay of ETS2 mRNA, thereby suppressing the ETS2/ZDHHC21/STING axis, reducing STING palmitoylation and downstream pyroptosis, and alleviating lung injury. This pathway highlights AUF1 as a potential therapeutic target for sepsis-induced ALI Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1